Spectrum Therapeutics provides update on its global clinical research program and unveils pharmacovigilance program

Spectrum Therapeutics (“Spectrum”), the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (the “Company” or “Canopy Growth”) is pleased to share an update…

Spectrum Therapeutics (“Spectrum”), the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (the “Company” or “Canopy Growth”) is pleased to share an update on its efforts to develop and commercialize validated cannabis medicines through clinical trials. Demand for cannabinoid-based medicines is emerging around the world. With a highly experienced scientific team and the […]

The post Spectrum Therapeutics provides update on its global clinical research program and unveils pharmacovigilance program appeared first on Technical420.

Leave a Reply

Your email address will not be published. Required fields are marked *